Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...

Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL cholesterol with a strong safety profile. ・The company plans to advance the ...

Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse ...

Through a $650,000 USDA Grant Yi Li will study the unintended consequences of multiplex genome editing and how many ...

Many plants including cocoa, coffee and avocado cannot be gene-edited but a technique involving grafting could change that, ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...